Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024HeliyonOpen Access

Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJun ZhaoYFYujie FengGLGuangwei Liu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhao et al. (2024) studied this question.

synapsesocial.com/papers/68e76604b6db6435876db630https://doi.org/10.1016/j.heliyon.2024.e27832
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors2019 · 1,177 citations
  2. 2Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010 · 15,355 citations
  3. 3Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015 · 9,564 citations
  4. 4Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline2018 · 3,765 citations
  5. 5Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy2022 · 118 citations